OTCMKTS:FSNUY Fresenius SE & Co. (FSNUY) Stock Price, News & Analysis $12.30 -0.09 (-0.73%) As of 11:15 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartDividendEarningsHeadlinesShort InterestBuy This Stock About Fresenius SE & Co. Stock (OTCMKTS:FSNUY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Fresenius SE & Co. alerts:Sign Up Key Stats Today's Range$12.26▼$12.3650-Day Range$11.72▼$12.8552-Week Range$7.88▼$12.97Volume5,535 shsAverage Volume53,632 shsMarket CapitalizationN/AP/E Ratio64.74Dividend Yield1.54%Price TargetN/AConsensus RatingBuy Company Overview Fresenius SE & Co. KGaA is a global health care group headquartered in Bad Homburg, Germany. Founded in 1912 by pharmacist Eduard Fresenius, the company has grown through strategic acquisitions and innovation to become one of the world’s leading providers of medical products and services. Over more than a century, Fresenius has expanded its footprint across Europe, the Americas, Asia and Africa, serving patients and healthcare professionals in more than 100 countries. The company operates through four core business segments. Fresenius Medical Care specializes in dialysis products and services for patients with chronic kidney failure. Fresenius Kabi develops and manufactures clinical nutrition products, infusion therapies and medical devices for hospital and outpatient care. Fresenius Helios is one of Europe’s largest private hospital operators, overseeing more than 130 acute care hospitals and numerous outpatient centers. VAMED provides project management, technical services and solutions for healthcare facilities, supporting clients from planning and construction through operations and maintenance. Fresenius places a strong emphasis on research and development, investing in innovations ranging from biopharmaceutical manufacturing to digital health solutions. Its leadership team is headed by Chief Executive Officer Dr. Stephan Sturm and Chief Financial Officer Dr. Marcus Both, under the oversight of a Supervisory Board chaired by Georg Funke. With a commitment to improving patient outcomes and increasing access to quality care, the company continues to pursue strategic partnerships and sustainable growth initiatives in key markets worldwide.AI Generated. May Contain Errors. Read More Receive FSNUY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fresenius SE & Co. and its competitors with MarketBeat's FREE daily newsletter. Email Address FSNUY Stock News HeadlinesFresenius Medical in-pact with Coordination of National Institutes in MexicoJuly 3, 2025 | msn.comFSNUY Fresenius SE & Co. KGaA - Seeking AlphaJune 28, 2025 | seekingalpha.comBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket change. July 11 at 2:00 AM | Crypto 101 Media (Ad)Fresenius: Healthy Portfolio AddJune 7, 2025 | seekingalpha.comFresenius SE price target raised to EUR 52 from EUR 43 at CitiJune 5, 2025 | msn.comThree Days Left Until Fresenius SE & Co. KGaA (ETR:FRE) Trades Ex-DividendMay 22, 2025 | finance.yahoo.comBerenberg Increases Price Target for Fresenius SE (FSNUY) | FSNUY Stock NewsMay 12, 2025 | gurufocus.comFresenius SE & Co. KGaA (FSNUF) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comSee More Headlines FSNUY Stock Analysis - Frequently Asked Questions How have FSNUY shares performed this year? Fresenius SE & Co.'s stock was trading at $8.75 at the beginning of the year. Since then, FSNUY shares have increased by 40.6% and is now trading at $12.30. How were Fresenius SE & Co.'s earnings last quarter? Fresenius SE & Co. (OTCMKTS:FSNUY) issued its quarterly earnings results on Wednesday, May, 7th. The company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.01. The business had revenue of $5.92 billion for the quarter, compared to analyst estimates of $5.41 billion. Fresenius SE & Co. had a net margin of 1.92% and a trailing twelve-month return on equity of 9.06%. How do I buy shares of Fresenius SE & Co.? Shares of FSNUY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/07/2025Ex-Dividend for 6/4 Dividend5/27/2025Record date for 6/4 Dividend5/28/2025Dividend Payable6/04/2025Today7/10/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - OUTP/HM CRE Sub-IndustryMedical Equipment Current SymbolOTCMKTS:FSNUY CIKN/A Webwww.fresenius.com Phone(496) 172-6080FaxN/AEmployees176,486Year Founded1912Profitability EPS (Trailing Twelve Months)$0.19 Trailing P/E Ratio65.21 Forward P/E Ratio15.68 P/E GrowthN/ANet Income$509.67 million Net Margins1.92% Pretax Margin7.17% Return on Equity9.06% Return on Assets4.17% Debt Debt-to-Equity Ratio0.50 Current Ratio1.43 Quick Ratio1.11 Sales & Book Value Annual Sales$23.63 billion Price / SalesN/A Cash Flow$1.28 per share Price / Cash Flow9.68 Book Value$9.83 per share Price / Book1.26Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.75 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (OTCMKTS:FSNUY) was last updated on 7/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fresenius SE & Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fresenius SE & Co. With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.